This ICR describes the burden to
manufacturers when they request Clinical Laboratory Improvement
Amendments of 1998 (CLIA) categorization of in vitro diagnostic
(IVD) tests when a premarket review is not needed (for example,
devices exempt from premarket notification). In these cases, FDA
recommends that manufacturers submit to FDA a brief description of
why CLIA categorization is requested (e.g., exempt from 510(k),
name change for a previously cleared device), the name of the
device, the package insert (instructions for use), the product
code, and regulation number. FDA will use the information collected
to determine device complexity. There are three categories of test
complexity: waived tests, moderate complexity tests, and high
complexity tests. Laboratories performing only waived tests are
subject to minimal regulation. Laboratories performing moderate or
high complexity tests are subject to specific laboratory standards
governing certification, personnel, proficiency testing, patient
test management, quality assurance, quality control, and
inspections.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.